ReviewDepression and anxiety2025
MicroRNAs as Regulators of Neuroinflammation in Major Depressive Disorder.
Review in Depression and anxiety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Engineering Advanced Nanomedicine Against Depression: From Treatment Challenges to Delivery Strategies.Advanced healthcare materials · 2026Review
- METTL3-dependent m⁶A maturation of miR-140-3p contributes to hippocampal neuronal apoptosis through the OTX2/Wnt/β-catenin axis under chronic stress.Molecular biology reports · 2026Article
- Central neuroendocrine dysregulation in ischaemic stroke sequelae: pathophysiological mechanisms-a narrative review.Frontiers in human neuroscience · 2026Review
- The Fractalkine (FKN/CX3CL1) Pathway in Depression: A Critical Review of Its Role in Neuroinflammation and Therapeutic Potential.Neuropsychiatric disease and treatment · 2026Review
- MicroRNAs as Regulators of Neuroinflammation in Major Depressive Disorder.Depression and anxiety · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is a globally prevalent mental health condition with a complex pathogenesis and substantial disease burden. However, due to incomplete mechanistic understanding, existing therapeutic strategies frequently yield suboptimal outcomes. This review synthesizes evidence establishing neuroinflammation as a central pathogenic mechanism of MDD, involving elevated proinflammatory cytokines, microglial M1 polarization, blood-brain barrier (BBB) disruption, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, and impaired neuroplasticity. Micro ribonucleic acid (miRNA) are identified as master molecular regulators bridging neuroinflammation and MDD pathology with details of how specific dysregulated miRNAs orchestrate MDD processes by targeting key inflammatory pathways, directing microglial polarization states, mediating intercellular communication via exosomes, and modulating BBB integrity. Crucially, these miRNAs may serve as novel diagnostic biomarkers and therapeutic targets for MDD. Building on this, we explore the potential of natural compounds as innovative miRNA-targeting therapeutics that can ameliorate neuroinflammation and restore neuroplasticity. Current challenges relating to clinical translation are discussed, including discordance between peripheral and brain miRNA profiles, species-specific miRNA functional variations, limited biomarker specificity across psychiatric disorders, the absence of standardized clinical reference ranges, and the need for more effective delivery systems. Overall, this review positions miRNA-mediated neuroinflammation regulation as a transformative frontier for MDD pathogenesis research and targeted treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.